limk inhibitor Search Results


bms-3  (MedChemExpress)
94
MedChemExpress bms-3
Bms 3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bms-3/product/MedChemExpress
Average 94 stars, based on 1 article reviews
bms-3 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
potent limk1 inhibitors based on an aminothiazole scaffold  (Bristol Myers)
90
Bristol Myers potent limk1 inhibitors based on an aminothiazole scaffold
Potent Limk1 Inhibitors Based On An Aminothiazole Scaffold, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/potent limk1 inhibitors based on an aminothiazole scaffold/product/Bristol Myers
Average 90 stars, based on 1 article reviews
potent limk1 inhibitors based on an aminothiazole scaffold - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
bms-5  (Cayman Chemical)
90
Cayman Chemical bms-5
Bms 5, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bms-5/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
bms-5 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
selective inhibitor of limk activity  (Bristol Myers)
90
Bristol Myers selective inhibitor of limk activity
<t>LIMK</t> <t>activity</t> promotes VSMC migration. The activation of RhoA/ROCK by stimuli such as PDFG-BB leads to the phosphorylation of LIMK and inactivation of cofilin, thereby promoting actin polymerization. Concurrently, ROCK phosphorylates MLCP and inhibits its activity, resulting in increased phosphorylation of MLC and subsequent VSMC contraction. Activation of inflammatory cytokines such as CCR8, CKLF1, and CXCL12 also modulates cell migration via lamellipodia formation. These inflammatory processes likely promote VSMC migration in a LIMK-dependent manner. Whether inflammatory cytokines activate LIMK via Rac2 activation remains unknown. (PDFG-BB: Platelet derived growth factor BB; Arp 2/3: Actin related protein 2/3; CCR8: chemokine receptor-8; CKLF1: Chemokine-like factor 1; CXCL12: C-X-C motif chemokine 12; MLCP: Myosin light chain phosphatase).
Selective Inhibitor Of Limk Activity, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selective inhibitor of limk activity/product/Bristol Myers
Average 90 stars, based on 1 article reviews
selective inhibitor of limk activity - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
biochemical assays for all limk inhibitors and kinase profiling  (Reaction Biology Corporation)
90
Reaction Biology Corporation biochemical assays for all limk inhibitors and kinase profiling
<t>LIMK</t> <t>activity</t> promotes VSMC migration. The activation of RhoA/ROCK by stimuli such as PDFG-BB leads to the phosphorylation of LIMK and inactivation of cofilin, thereby promoting actin polymerization. Concurrently, ROCK phosphorylates MLCP and inhibits its activity, resulting in increased phosphorylation of MLC and subsequent VSMC contraction. Activation of inflammatory cytokines such as CCR8, CKLF1, and CXCL12 also modulates cell migration via lamellipodia formation. These inflammatory processes likely promote VSMC migration in a LIMK-dependent manner. Whether inflammatory cytokines activate LIMK via Rac2 activation remains unknown. (PDFG-BB: Platelet derived growth factor BB; Arp 2/3: Actin related protein 2/3; CCR8: chemokine receptor-8; CKLF1: Chemokine-like factor 1; CXCL12: C-X-C motif chemokine 12; MLCP: Myosin light chain phosphatase).
Biochemical Assays For All Limk Inhibitors And Kinase Profiling, supplied by Reaction Biology Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biochemical assays for all limk inhibitors and kinase profiling/product/Reaction Biology Corporation
Average 90 stars, based on 1 article reviews
biochemical assays for all limk inhibitors and kinase profiling - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
limk inhibitor s3  (AnaSpec)
90
AnaSpec limk inhibitor s3
<t>LIMK</t> <t>activity</t> promotes VSMC migration. The activation of RhoA/ROCK by stimuli such as PDFG-BB leads to the phosphorylation of LIMK and inactivation of cofilin, thereby promoting actin polymerization. Concurrently, ROCK phosphorylates MLCP and inhibits its activity, resulting in increased phosphorylation of MLC and subsequent VSMC contraction. Activation of inflammatory cytokines such as CCR8, CKLF1, and CXCL12 also modulates cell migration via lamellipodia formation. These inflammatory processes likely promote VSMC migration in a LIMK-dependent manner. Whether inflammatory cytokines activate LIMK via Rac2 activation remains unknown. (PDFG-BB: Platelet derived growth factor BB; Arp 2/3: Actin related protein 2/3; CCR8: chemokine receptor-8; CKLF1: Chemokine-like factor 1; CXCL12: C-X-C motif chemokine 12; MLCP: Myosin light chain phosphatase).
Limk Inhibitor S3, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/limk inhibitor s3/product/AnaSpec
Average 90 stars, based on 1 article reviews
limk inhibitor s3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
limk inhibitor crt0105950 small molecule  (CancerTools Org)
N/A
The LIMK inhibitor CRT0105950 is a novel, selective, potent LIMK inhibitor, which inhibits p-cofilin and inhibits invasion in a Matrigel inverse invasion assay. LIMK1 has been reported to play a key role in tumour cell
   Buy from Supplier

Image Search Results


LIMK activity promotes VSMC migration. The activation of RhoA/ROCK by stimuli such as PDFG-BB leads to the phosphorylation of LIMK and inactivation of cofilin, thereby promoting actin polymerization. Concurrently, ROCK phosphorylates MLCP and inhibits its activity, resulting in increased phosphorylation of MLC and subsequent VSMC contraction. Activation of inflammatory cytokines such as CCR8, CKLF1, and CXCL12 also modulates cell migration via lamellipodia formation. These inflammatory processes likely promote VSMC migration in a LIMK-dependent manner. Whether inflammatory cytokines activate LIMK via Rac2 activation remains unknown. (PDFG-BB: Platelet derived growth factor BB; Arp 2/3: Actin related protein 2/3; CCR8: chemokine receptor-8; CKLF1: Chemokine-like factor 1; CXCL12: C-X-C motif chemokine 12; MLCP: Myosin light chain phosphatase).

Journal: Frontiers in Physiology

Article Title: LIM kinases in cardiovascular health and disease

doi: 10.3389/fphys.2024.1506356

Figure Lengend Snippet: LIMK activity promotes VSMC migration. The activation of RhoA/ROCK by stimuli such as PDFG-BB leads to the phosphorylation of LIMK and inactivation of cofilin, thereby promoting actin polymerization. Concurrently, ROCK phosphorylates MLCP and inhibits its activity, resulting in increased phosphorylation of MLC and subsequent VSMC contraction. Activation of inflammatory cytokines such as CCR8, CKLF1, and CXCL12 also modulates cell migration via lamellipodia formation. These inflammatory processes likely promote VSMC migration in a LIMK-dependent manner. Whether inflammatory cytokines activate LIMK via Rac2 activation remains unknown. (PDFG-BB: Platelet derived growth factor BB; Arp 2/3: Actin related protein 2/3; CCR8: chemokine receptor-8; CKLF1: Chemokine-like factor 1; CXCL12: C-X-C motif chemokine 12; MLCP: Myosin light chain phosphatase).

Article Snippet: Since the first report on the development of a selective inhibitor of LIMK activity by Bristol-Myers-Squibb in 2006, only one such molecule has reached clinical trials for treating glaucoma ( ).

Techniques: Activity Assay, Migration, Activation Assay, Phospho-proteomics, Derivative Assay

Representative studies on the role of LIMK in cardiovascular diseases.

Journal: Frontiers in Physiology

Article Title: LIM kinases in cardiovascular health and disease

doi: 10.3389/fphys.2024.1506356

Figure Lengend Snippet: Representative studies on the role of LIMK in cardiovascular diseases.

Article Snippet: Since the first report on the development of a selective inhibitor of LIMK activity by Bristol-Myers-Squibb in 2006, only one such molecule has reached clinical trials for treating glaucoma ( ).

Techniques: Migration